One advantage of blood donation is that these insoluble protein products and inflammatory agents may be removed in the process. Therefore, patients who donate blood frequently may reduce the total amount of amyloid precursor protein (APP) and the interleukin 1 that has a role in regulating APP's synthesis.⁹

If the authors have this information perhaps they can assess the risk of developing AD with the amount of blood donated. I would predict that the risk of developing AD is inversely proportional to the amount of blood donated over a person's lifetime.

Daniel L. Menkes, Memphis, TN

Disclosure: The author reports no conflicts of interest.

Reply from the Author: We thank Dr. Menkes et al. for their interest in our report and for their interesting hypothesis. We do not have systematic data on the blood donation habits of Framingham Study participants and hence we can neither support nor refute the author's hypothesis. However, while our study found a relationship between peripheral blood mononuclear cell production of cytokines and the risk of AD, we found no such relationship between serum cytokines concentrations and incident AD.

Zaldy S. Tan, MD, MPH, Boston, MA

Disclosure: The author reports no conflicts of interest.

Copyright © 2008 by AAN Enterprises, Inc.

1. Tan ZS, Beiser AS, Vasan RS, et al. Inflammatory markers and the risk of Alzheimer disease: The Framingham Study. *Neurology* 2007;68:1902–1908.
2. Banks WA, Kastin AJ, Broadwell RD. Passage of cytokines across the blood-brain barrier. *Neuroimmunomodulation* 1995;2:241–248.
3. Ramos EM, Lin MT, Larson EB, et al. Tumor necrosis factor alpha and interleukin 10 promoter region polymorphisms and risk of late-onset Alzheimer disease. *Arch Neurol* 2006;63:1165–1169.
4. Tobinick E, Gross H, Weinberger A, Cohen H. TNF-alpha modulation for treatment of Alzheimer's disease: a 6-month pilot study. *Medscape General Medicine* 2006;8:25.
5. Goddard CA, Butts DA, Shatz CJ. Regulation of CNS synapses by neuronal MHC class I. *Proc Natl Acad Sci USA* 2007;104:6828–6833.
6. Vinters HV. Cerebral amyloid angiopathy: a critical review. *Stroke* 1987;18:311–324.
7. Kliman A, Carbone PP, Gaydos LA, Freireich EJ. Effect of intensive plasmapheresis on normal blood donors. *Blood* 1964;23:647–656.
8. Weisbach V, Wanke C, Zingsem J, Zimmermann R, Eckstein R. Cytokine generation in whole blood, leukocyte-depleted and temporarily warmed red blood cell concentrates. *Vox Sanguinis* 1999;76:100–106.
9. Goldgaber D, Harris HW, Hla T, et al. Interleukin 1 regulates synthesis of amyloid α -protein precursor mRNA in human endothelial cells. *PNAS* 1989;76:606–610.

CORRECTION

Practice Parameter: Treatment of nervous system Lyme disease (an evidence-based review): Report of the Quality Standards Subcommittee of the American Academy of Neurology

For the Special Article "Practice Parameter: Treatment of nervous system Lyme disease (an evidence-based review): Report of the Quality Standards Subcommittee of the American Academy of Neurology," by J.J. Halperin et al. (*Neurology*® 2007;69:91–102), the following Conflict of Interest statement was inadvertently omitted. The Academy regrets the error.

Dr. Halperin holds equity in Abbott, Bristol Myers Squibb, Johnson & Johnson, Schering Plough, and Vasogen. He has served as an expert witness in medical malpractice actions. Dr. Shapiro has received funds for reviewing disability claims from Metropolitan Life Insurance Company and has served as an expert witness in malpractice actions. He has also received honoraria from Merck, Inc. and Aventis for speaking engagements. Dr. Shapiro receives funding from NIH grants K24RR022477, KL2RR024138, and UL1RR024139. Dr. Logigian has been a consultant to Actelion Pharmaceuticals, Ltd. and served as an expert witness in a Lyme disease case in 2004. Dr. Belman has nothing to disclose. Dr. Dotevall has received monies from Pfizer for lecturing. Dr. Wormser reports having received research grants related to Lyme disease from the Centers for Disease Control and Prevention, the National Institutes of Health, Immunetics, Inc., and BioRad. He was part owner of Diaspex, LLC, a company with no products or services. He has been an expert witness for the United States in a medical malpractice case and has been retained in other medical practice cases involving Lyme disease. Dr. Wormser has overseen educational grants to New York Medical College to support Infectious Diseases grand rounds from Merck and AstraZeneca, and one from Pfizer is expected in 2008. Dr. Krupp has no conflicts of interest to report. Dr. Gronseth holds financial interests in Pfizer and GlaxoSmithKline, has received speaker honoraria from Boehringer Ingelheim, and has received honoraria from Ortho-McNeil for serving on the IDMC Committee. Dr. Bever has received honoraria from Teva Pharmaceuticals, Berlex Laboratories, Serono, Pfizer, Senofi-Aventis, and Accordia Therapeutics. Dr. Bever has received research funding from Serono and Accordia Therapeutics.

Neurology®

CORRECTION

Neurology 2008;70;1223
DOI 10.1212/01.wnl.0000314147.03262.b6

This information is current as of March 31, 2008

Updated Information & Services

including high resolution figures, can be found at:
<http://n.neurology.org/content/70/14/1223.full>

Permissions & Licensing

Information about reproducing this article in parts (figures, tables) or in its entirety can be found online at:
http://www.neurology.org/about/about_the_journal#permissions

Reprints

Information about ordering reprints can be found online:
<http://n.neurology.org/subscribers/advertise>

Neurology® is the official journal of the American Academy of Neurology. Published continuously since 1951, it is now a weekly with 48 issues per year. Copyright . All rights reserved. Print ISSN: 0028-3878. Online ISSN: 1526-632X.